Tamtam Try Tamtam free
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals account plan

Developing RNAi therapeutics

At a glance

Alnylam Pharmaceuticals is an RNAi biopharmaceutical company with six approved medicines, led by AMVUTTRA; about 2,500 employees.

Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company built on RNA interference (RNAi), headquartered in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland. It has six approved first-in-class RNAi medicines: it sells AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO itself, mainly in the U.S. and Europe, and earns royalties on Leqvio (Novartis) and Qfitlia (Sanofi). FY2025 total revenues were $3,713,937 thousand (+65%), and the company reached profitability for the first time, with net income of $313,747 thousand. It had about 2,500 full-time employees at 31 December 2025, about 1,945 of them in the U.S.

Business units

Strategic priorities

Alnylam 2030 revenue and margin targets
The Alnylam 2030 strategy, launched early 2026, targets a 25%+ total revenue CAGR through year-end 2030 and ~30% non-GAAP operating margin, reinvesting ~30% of revenues in non-GAAP R&D.
TTR market leadership
Alnylam aims to lead the market in TTR revenue by 2030 and launch nucresiran in ATTR polyneuropathy by 2028 and cardiomyopathy by 2030; the CEO frames growth around capturing a third of U.S. category TRx in a treated ATTR-CM population of about 75,000 by 2030.
Expanding the AMVUTTRA prescriber base
The field force was expanded by about 25% to reach the two-thirds of targeted physicians who have not yet prescribed AMVUTTRA; about 80% of prevalent ATTR-CM patients remain untreated.
New medicines beyond TTR
The strategy targets 2+ new blockbuster-potential medicines beyond TTR, 10 tissue types and >40 clinical programs; brezosiran for Huntington's disease heads to a pivotal study in 2027.
Lower production costs
The Norton, Massachusetts plant is being expanded for the siRELIS enzymatic ligation platform to increase capacity and reduce production costs; nucresiran carries no Sanofi royalties.

Latest results

In Q3 2026 total revenues were $1,458,086 thousand (+17%) and net product revenues $1,291,946 thousand (+52%), with AMVUTTRA at $1,130,363 thousand (+65%). Total revenues were held back by comparison with the $300.0 million Roche milestone of Q3 2025, and income from operations fell 6% to $345,798 thousand as cost of goods sold reached 28.0% of net product revenues on higher Sanofi royalties. Net income of $2,167,335 thousand included a $1,871,525 thousand tax benefit. Nine-month revenues were $3,916,209 thousand (+50%). 2026 guidance was reiterated at net product revenues of $4,700 million - $5,100 million, with TTR sales expected at the low end of the $4.2 billion-$4.5 billion range; 2027 guidance moves to mid-February.

Investments and deals

Norton manufacturing expansion
Expansion of the 200,000 sq ft Norton, Massachusetts drug-substance plant, announced in December 2025, adds the siRELIS enzymatic ligation platform. FY2025 capital expenditures were $58.7 million, expected to increase in 2026.
Phase 3 trials
R&D spend was $1,319,775 thousand in FY2025, driven by the ZENITH, TRITON-CM and TRITON-PN Phase 3 trials; TRITON-CM enrollment was expanded twice in 2026 to about 2,250 patients.
AI collaboration with Inceptive Nucleics
A June 2026 collaboration integrates Inceptive's generative AI models with Alnylam's pipeline, with a $15.0 million purchase of Inceptive preferred stock.
Field force expansion
The sales field force was expanded by about 25% to raise physician engagement for AMVUTTRA.
Convertible refinancing and credit facility
In September 2025 Alnylam issued $661.3 million of 0.00% convertible notes due 2028 and entered a $500.0 million revolving credit facility, undrawn.

Challenges and risks

Slower AMVUTTRA demand growth
The CEO said Alnylam is not yet satisfied with underlying demand growth; the expanded sales force is raising engagement but not yet patient starts, and no acceleration is expected in Q4 2026.
340B and payer restrictions
A CMS 340B reimbursement change from ASP +6% to ASP -28% takes effect January 1, 2027, and UnitedHealth and Aetna added step edits.
Rising royalty costs
Cost of goods sold rose to 28.0% of net product revenues in Q3 2026 from 23.2% as the blended Sanofi royalty rate on AMVUTTRA rose, with tiers up to 30%.
Dependence on AMVUTTRA and competition
The 10-K names dependence on AMVUTTRA as a key risk, with competition from tafamidis, acoramidis, eplontersen and gene editing.
First-line patient mix
2026 TTR guidance was cut to $4.2 billion-$4.5 billion as the patient mix moved toward the market's 80% first line / 20% second line.

What leadership says

“we're not yet satisfied with the underlying demand growth we have observed”

Yvonne Greenstreet, Chief Executive Officer · Q3 2026 earnings call, October 29, 2026

“laser focused on leveraging our commercial investments to expand the prescriber base, support access, and bring AMVUTTRA to more patients”

Yvonne Greenstreet, Chief Executive Officer · Third quarter 2026 financial results press release, October 29, 2026

“in cardiology, behavioral change takes some time”

Yvonne Greenstreet, Chief Executive Officer · Jefferies Global Healthcare Conference fireside chat, November 18, 2026

“crossed a billion of revenue in just one quarter”

Yvonne Greenstreet, Chief Executive Officer · Morgan Stanley Global Healthcare Conference fireside chat, September 14, 2026, on AMVUTTRA in Q2 2026

Where a supplier can help

Commercial targeting and field-force effectiveness
Tied to the prescriber-base priority and the slower demand growth: physician targeting data, CRM analytics and omnichannel engagement help the expanded field force turn engagement into patient starts.
Market access and 340B contracting
Tied to the 340B reimbursement change and payer step edits: contracting, reimbursement and patient-access services support the work with about 200 340B institutions.
Manufacturing scale-up at Norton
Tied to the Norton expansion and lower production costs: process equipment, engineering and quality services fit the siRELIS build-out.
Clinical trial delivery
Tied to the three Phase 3 trials and the enlarged TRITON-CM study: CRO capacity, patient recruitment and trial data services address heavier clinical spend.
AI and data for discovery
Tied to the Inceptive Nucleics collaboration and the >40 clinical programs target: AI, data infrastructure and genetics partners support pipeline expansion.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Alnylam Pharmaceuticals?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Alnylam Pharmaceuticals

What does Alnylam Pharmaceuticals do?

Alnylam develops and sells RNA interference (RNAi) medicines that silence the genes behind disease. It has six approved RNAi medicines, led by AMVUTTRA for ATTR amyloidosis.

What is Alnylam's revenue?

FY2025 total revenues were $3,713,937 thousand, up 65%, with net income of $313,747 thousand. Q3 2026 total revenues were $1,458,086 thousand (+17%).

How many employees does Alnylam have?

About 2,500 full-time employees at 31 December 2025, about 1,945 in the U.S., after about 270 were added in 2025.

Who leads Alnylam?

Yvonne Greenstreet is Chief Executive Officer; Jeff Poulton is CFO and Pushkal Garg leads R&D as CMO.

What is Alnylam's strategy?

The Alnylam 2030 strategy targets TTR market leadership, 2+ new blockbuster-potential medicines beyond TTR, a 25%+ revenue CAGR through 2030 and ~30% non-GAAP operating margin.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)